跳至主要内容
临床试验/NCT07017634
NCT07017634招募中3 期

Efficacy and Safety of Novosis Putty in Transforaminal Lumbar Interbody Fusion for Patients With Lumbar Degenerative Disc Disease : A Pivotal, Randomized, Prospective, Multi-Center Study

CGBio Inc.5 个研究点 分布在 1 个国家目标入组 316 人开始时间: 2026年6月11日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
316
试验地点
5
主要终点
Overall Success

研究概览

简要总结

Efficacy and Safety of Novosis Putty in Transforaminal Lumbar Interbody Fusion for Patients with Lumbar Degenerative Disc Disease : A Pivotal, Randomized, Prospective, Multi-Center Study

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
21 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Has a primary diagnosis of symptomatic lumbar degeneration with or without foraminal or recess stenosis of the lumbar confirmed by subject history and radiographic imaging (CT, MRI, X-rays) with no more than a Grade 2 (≤50% translation) spondylolisthesis. Symptomatic lumbar degeneration (L1 to S1) that may be associated with a co-morbid condition.
  • Has a history of failure conservative treatment (e.g. bed rest, physical therapy, medications, transcutaneous electrical nerve stimulation (TENS), manipulation, and/or spinal injections) for at least 6 months
  • Has preoperative Oswestry Disability Index score ≥ 40/100 at baseline
  • Male or Female, 21-80 years of age and skeletally mature at the time of surgery
  • Psychosocially, mentally and physically able to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms
  • Signed informed consent

排除标准

  • Previous instrumented surgery (i.e.: anterior disc replacement, spinal fusion, interspinous device, etc.) at the index lumbar level or an adjacent level;
  • Degenerative or lytic spondylolisthesis greater than Grade 2 (50% translation);
  • Active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years;
  • Any degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis;
  • Has chronic or acute renal and/or hepatic impairment and/or failure or prior history of renal and/or hepatic parenchymal disease;
  • Lactating, pregnant or interested in becoming pregnant in the next 3 years;
  • Is currently participating in an investigational therapy (device and/or pharmaceutical) within 30 days prior to entering the study or such treatment is planned during the 24 months following enrollment into the study.
  • Known hypersensitivity or allergy to any components of the study treatments inclusive of hypersensitivity or allergy to any BMP-2 type recombinant proteins or peptides.

研究组 & 干预措施

Novosis Putty

Experimental

干预措施: Novosis Putty (Device)

Standard of Care

Active Comparator

干预措施: Standard of Care (Other)

结局指标

主要结局

Overall Success

时间窗: 24 months after surgery

Meet all of the following conditions: 1. Fusion success 2. Oswestry Disability Index success 3. Neurological success 4. No subsequent surgical interventions 5. No related serious event

次要结局

  • Overall Success(6 and 12 months after surgery)
  • ODI score(6weeks, 3, 6, 12, 24, 36, 48 and 60months after surgery)
  • VAS score(6weeks, 3, 6, 12, 24, 36, 48 and 60months after surgery)
  • SF-12 score(6weeks, 3, 6, 12, 24, 36, 48 and 60months after surgery)
  • Fusion Success(12 months after surgery)
  • Fusion Success(6 and 24 months after surgery)
  • Time to Fusion Success(From surgery to 60 months after surgery)
  • Time to First SSI(From surgery to 60 months after surgery)
  • Treatment satisfaction(6weeks, 3, 6, 12, 24, 36, 48 and 60months after surgery)
  • Intraoperative variables(intraoperative)

研究者

发起方
CGBio Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验